Topics
May/June 2023 | Subfocus
Quantifying Fluid in AMD
Central subfoveal thickness isn’t the only biomarker clinicians can use to track disease progression and treatment effect.
Stela Vujosevic, MD, PhD, FARVO, FEBO
Clinical Trial Designs in Wet AMD: A Brief Review
Can newer therapies improve upon visual acuity and other outcomes for patients?
Carl D. Regillo, MD
The Effect of Biosimilars on Clinical Practice
A look at the true cost of the new drugs that are shaking up our therapeutic approaches.
Margaret M. Runner, MD, and George A. Williams, MD
August 26, 2026
Sightview Launches Updated Ophthalmology EHR and Practice Management Platform
August 24, 2026
Oculis Doses First Patient in Phase 3 PIONEER-1 Trial of Privosegtor for Optic Neuritis
August 19, 2026
Eyconis Initiates First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet AMD
August 17, 2026
Duravyu Misses Primary Endpoint in Phase 3 LUGANO Trial but Reduces Treatment Burden in Wet AMD
July/August 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
MEDIA PLACEMENT SPONSORED BY CARL ZEISS MEDITEC AG
July/August 2026 Supplement
Editorially Independent Content, Supported With Advertising From Astellas
Editorially Independent Content, Supported With Advertising From Astellas and ZEISS
July 2026 Supplement
Free Print Subscription
Email Newsletter
Conference Calendar
_1784132761.jpg?auto=compress,format&w=70)
